Trial Profile

An Open-label, Phase 1/2 Trial of Gene Therapy 4D-125 in Males With X-linked Retinitis Pigmentosa (XLRP) Caused by Mutations in the RPGR Gene

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 23 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

13 Nov 2024 According to a 4D Molecular Therapeutics media release, Program updates expected in early January 2025.
08 Aug 2024 According to a 4D Molecular Therapeutics media release,Program updates expected in Q4 2024.
09 Jan 2023 According to a 4D Molecular Therapeutics media release, enrollment in this phase 1/2 study has been completed in the fourth quarter of 2022. The company will continue to follow these patients for 24 months and anticipate clinical data updates in 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com